Eton Pharmaceuticals (ETON) vs Innoviva (INVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Innoviva (INVA) over the past year, gaining 159.5% versus a gain of 22.4%. Over five years, ETON leads with a +953.4% price change compared with +26.8% for INVA. Eton Pharmaceuticals is the larger company by market cap ($1.57 billion vs $1.51 billion), about 1.0 times the size.
On valuation, Innoviva trades at a lower forward P/E (9.4x vs 21.3x for Eton Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | INVA |
|---|---|---|
| Share price | $54.89 | $20.87 |
| Market cap | $1.57B | $1.51B |
| 1-day change | +0.02% | -0.90% |
| YTD return | +224.54% | +5.35% |
| 1-year return | +159.48% | +22.44% |
| 5-year return | +953.36% | +26.79% |
| P/E ratio (TTM) | 137.22 | 4.88 |
| Forward P/E | 21.28 | 9.44 |
| EPS (TTM) | $0.40 | $4.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $66.37 | $25.15 |
| 52-week low | $14.27 | $16.52 |
| Distance from 52-week high | -17.30% | -17.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +29.35% | +67.70% |
| Average volume | 606.07K | 819.96K |
| Shares outstanding | 28.58M | 72.25M |
| Employees | 44 | 159 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed INVA by 137.0 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (137.2x vs 4.9x trailing P/E).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
ETON vs INVA FAQ
Which is bigger, Eton Pharmaceuticals or Innoviva?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.57B compared with $1.51B for Innoviva (INVA).
Which stock has performed better over the past year, ETON or INVA?
ETON returned +159.48% over the past 12 months, compared with +22.44% for INVA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ETON or INVA?
INVA has the lower trailing P/E at 4.9, versus 137.2 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Eton Pharmaceuticals and Innoviva in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.